Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
97
result(s) for
"Berry, Cynthia"
Sort by:
Traditional Versus Electronic Resources for Students in Clinical Nursing Courses: A Pilot Study
Physicians are being asked to utilize computerized order entry systems, nurses are inputting their documentation into computer systems, laboratory and diagnostic study results are instantly available, and all of the information is quickly and easily accessible wherever it is needed to meet the needs of the patient. Competency in using technology to record and access patient information is crucial in the workplace.\\n In response to the opportunity to make comments about the study, feedback included: \"clinical instructor didn't provide resources,\" \"it wasn't carried out equally among clinical groups,\" \"my instructor never mentioned anything about it.\"
Journal Article
Meeting Magnet research evidence-based practice expectations through hospital-based research centers
Hospital-based nursing research centers can create the structures and processes needed to promote and sustain research and evidence-based practice (EBP) and assist in the monitoring of care delivery outcomes. At the University of Rochester Medical Center, New York, a highly successful nursing research center has succeeded in creating a Magnet environment that incorporates research and EBP into strategic planning, individual employee performance review, and organizational processes. Support of a hospital-based research center can provide the foundation for an infrastructure that supports achievement of Magnet designation research and EBP criteria. The costs pertain primarily to the staff required to develop and manage the center and the educational programs offered through it. Based on the experience at this center, administrators should plan 3-5 years before significant impact is seen in terms of numbers of consultations performed and tangible increases in staff and leadership participation in research and EBP initiatives.
Journal Article
Effect of Concord Grape Juice on Chemotherapy-Induced Nausea and Vomiting: Results of a Pilot Study
To determine the feasibility of administering a flavonoid-rich adjunctive treatment (Concord grape juice) for the management of chemotherapy-induced nausea and vomiting (CINV); to evaluate the usefulness of existing measures for assessing CINV frequency and severity, quality of life, control over life events, and psychological state; to identify any actual or potential adverse events associated with frequent grape juice intake; and to provide preliminary data concerning the effect of Concord grape juice on CINV, quality of life, perceived control over life events, and psychological state.
Double-blind, randomized clinical trial.
A cancer center in an academic health science center in the northeastern United States.
77 adult patients with cancer receiving moderately or highly emetogenic chemotherapy agents.
Participants drank 4 oz. of grape juice or placebo prior to meals for one week following each of four chemotherapy treatment cycles. They recorded frequency, duration, and distress of nausea, vomiting, and retching daily, beginning the evening of chemotherapy administration and continuing for seven days. Data were analyzed with generalized estimating equations methodology to model differences between groups over time.
Nausea and vomiting frequency, duration, and distress; quality of life; control over decision making; and psychological state.
Nausea and vomiting frequency, duration, and distress were lower for experimental group members, although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time. Greater levels of anxiety, depression, and hostility at baseline were related to nausea and vomiting, quality of life, and perceived control over decision making.
The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported. Alterations to the study protocol will be necessary to decrease attrition.
Flavonoid-rich fruits and vegetables may provide additional protection against CINV. If the compounds work, they would offer a low-cost, readily available adjunctive treatment for the management of CINV.
Journal Article
Covalent inhibitors of the RAS binding domain of PI3Kα impair tumor growth driven by RAS and HER2
Genetic disruption of the RAS binding domain (RBD) of PI 3-kinase (PI3K) prevents the growth of mutant RAS driven tumors in mice and does not impact PI3K's role in insulin mediated control of glucose homeostasis. Selectively blocking the RAS-PI3K interaction may represent an attractive strategy for treating RAS-dependent cancers as it would avoid the toxicity associated with inhibitors of PI3K lipid kinase activity such as alpelisib. Here we report compounds that bind covalently to cysteine 242 in the RBD of PI3K p110α and block the ability of RAS to activate PI3K activity. These inhibitors have a profound impact on the growth of RAS mutant and also HER2 over-expressing tumors, particularly when combined with other inhibitors of the RAS/MAPK pathway, without causing hyperglycemia.
Journal Article
Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2
Genetic disruption of the RAS binding domain (RBD) of PI 3-kinase (PI3K) prevents the growth of mutant RAS driven tumors in mice and does not impact PI3Ks role in insulin mediated control of glucose homeostasis. Selectively blocking the RAS-PI3K interaction may represent an attractive strategy for treating RAS-dependent cancers as it would avoid the toxicity associated with inhibitors of PI3K lipid kinase activity such as alpelisib. Here we report compounds that bind covalently to cysteine 242 in the RBD of PI3K p110a and block the ability of RAS to activate PI3K activity. These inhibitors have a profound impact on the growth of RAS mutant and also HER2 over-expressing tumors, particularly when combined with other inhibitors of the RAS/MAPK pathway, without causing hyperglycemia.Competing Interest StatementJ.E.K., N.R., S.M.B., S.G., M.A.H., H.M., J.T., J.W., C.B., A.E.O., R.L., Y.L., M.P., H.P., I.M., A.N.S., E.J.W., T.E.W., E.A., K.B., B.D.H., K.N.L., W.L., J.M., M.K.P., J.P., J.J.S., G.M.S., D.S.W., M.P.P are current employees of Vividion Therapeutics. J.C.B., J.M.C., K.H., E.T. and T.M.K. are former employees of Vividion Therapeutics. J.D. has acted as a consultant for AstraZeneca, Jubilant, Theras, Roche, Boehringer Ingelheim and Kestrel Therapeutics and has funded research agreements with Bristol Myers Squibb, Revolution Medicines, Vividion, Novartis and AstraZeneca. M.M.A., M.I., S.R., and M.T. have no competing interests to declare.Footnotes* Corrected typos/mislabeling on Figure 2 and Figure 5E
Paper
